Hong Kong · Delayed Price · Currency is HKD Innovent Biologics Statistics
Total Valuation
HKG:1801 has a market cap or net worth of HKD 170.70 billion. The enterprise value is 150.29 billion.
| Market Cap | 170.70B |
| Enterprise Value | 150.29B |
Important Dates
The next estimated earnings date is Wednesday, November 25, 2026.
| Earnings Date | Nov 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:1801 has 1.74 billion shares outstanding. The number of shares has increased by 7.87% in one year.
| Current Share Class | 1.74B |
| Shares Outstanding | 1.74B |
| Shares Change (YoY) | +7.87% |
| Shares Change (QoQ) | +0.75% |
| Owned by Insiders (%) | 6.55% |
| Owned by Institutions (%) | 53.65% |
| Float | 1.62B |
Valuation Ratios
The trailing PE ratio is 122.05 and the forward PE ratio is 46.90.
| PE Ratio | 122.05 |
| Forward PE | 46.90 |
| PS Ratio | 9.41 |
| PB Ratio | 7.13 |
| P/TBV Ratio | 7.67 |
| P/FCF Ratio | 11.43 |
| P/OCF Ratio | 11.14 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 75.99, with an EV/FCF ratio of 10.06.
| EV / Earnings | 105.63 |
| EV / Sales | 8.29 |
| EV / EBITDA | 75.99 |
| EV / EBIT | 123.92 |
| EV / FCF | 10.06 |
Financial Position
The company has a current ratio of 2.68, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.68 |
| Quick Ratio | 2.35 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 1.27 |
| Debt / FCF | 0.18 |
| Interest Coverage | 19.67 |
Financial Efficiency
Return on equity (ROE) is 7.01% and return on invested capital (ROIC) is 30.16%.
| Return on Equity (ROE) | 7.01% |
| Return on Assets (ROA) | 2.23% |
| Return on Invested Capital (ROIC) | 30.16% |
| Return on Capital Employed (ROCE) | 3.61% |
| Weighted Average Cost of Capital (WACC) | 5.54% |
| Revenue Per Employee | 2.07M |
| Profits Per Employee | 162,526 |
| Employee Count | 8,754 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 2.46 |
Taxes
In the past 12 months, HKG:1801 has paid 370.68 million in taxes.
| Income Tax | 370.68M |
| Effective Tax Rate | 20.67% |
Stock Price Statistics
The stock price has increased by +4.75% in the last 52 weeks. The beta is 0.25, so HKG:1801's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +4.75% |
| 50-Day Moving Average | 96.93 |
| 200-Day Moving Average | 87.26 |
| Relative Strength Index (RSI) | 49.46 |
| Average Volume (20 Days) | 11,261,159 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:1801 had revenue of HKD 18.13 billion and earned 1.42 billion in profits. Earnings per share was 0.80.
| Revenue | 18.13B |
| Gross Profit | 13.87B |
| Operating Income | 1.35B |
| Pretax Income | 1.79B |
| Net Income | 1.42B |
| EBITDA | 2.08B |
| EBIT | 1.35B |
| Earnings Per Share (EPS) | 0.80 |
Balance Sheet
The company has 23.09 billion in cash and 2.68 billion in debt, with a net cash position of 20.41 billion or 11.72 per share.
| Cash & Cash Equivalents | 23.09B |
| Total Debt | 2.68B |
| Net Cash | 20.41B |
| Net Cash Per Share | 11.72 |
| Equity (Book Value) | 23.95B |
| Book Value Per Share | 13.78 |
| Working Capital | 18.10B |
Cash Flow
In the last 12 months, operating cash flow was 15.33 billion and capital expenditures -391.81 million, giving a free cash flow of 14.93 billion.
| Operating Cash Flow | 15.33B |
| Capital Expenditures | -391.81M |
| Depreciation & Amortization | 746.49M |
| Net Borrowing | -1.28B |
| Free Cash Flow | 14.93B |
| FCF Per Share | 8.58 |
Margins
Gross margin is 76.51%, with operating and profit margins of 7.42% and 7.85%.
| Gross Margin | 76.51% |
| Operating Margin | 7.42% |
| Pretax Margin | 9.89% |
| Profit Margin | 7.85% |
| EBITDA Margin | 11.48% |
| EBIT Margin | 7.42% |
| FCF Margin | 81.24% |
Dividends & Yields
HKG:1801 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.87% |
| Shareholder Yield | -7.87% |
| Earnings Yield | 0.83% |
| FCF Yield | 8.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for HKG:1801 is 129.29, which is 31.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 129.29 |
| Price Target Difference | 31.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 30 |
| Revenue Growth Forecast (3Y) | 27.42% |
| EPS Growth Forecast (3Y) | 41.88% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HKG:1801 has an Altman Z-Score of 4.34 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.34 |
| Piotroski F-Score | 6 |